Sign inJoin waitlistJoin the waitlist

Charles Drescher

Affiliate Investigator, Translational Outcomes Research · University of Washington School of Medicine

Credentials: · · · ·

History

University of Washington School of Medicine
Present

Gynecologic Oncology
1988–1991
Obstetrics and Gynecology
1984–1988
University of Michigan Medical School
1978–1982

Research

Circulating microRNAs as stable blood-based markers for cancer detection
Proceedings of the National Academy of Sciences of the United States of America · 2008 · 6,537 citations
The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma
Cancer Research · 2003 · 557 citations
Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14
Nature Medicine · 2011 · 358 citations

WP
William Peters
11 papers
PP
Pamela Paley
9 papers
Beth Karlan
8 papers
Muneesh Tewari
8 papers
Chirag Shah
7 papers · 6 as a resident
Beatrice Knudsen
6 papers
Karen Lu
6 papers
Mary Daly
6 papers
MH
Michael Hopkins
6 papers · 2 as a fellow
Barbara Goff
5 papers
Ronny Drapkin
5 papers
Sanjiv Gambhir
5 papers

Grants

The Pacific Cancer Research Consortium (PCRC), an NCORP Community Site
National Cancer Institute · UG1
Contact PI · $15.9M · Swedish Medical Center, First Hill
2014–2027
Fred Hutchinson Breast Cancer Clinical Validation Center
National Cancer Institute · U01
PI · $5.3M · Fred Hutchinson Cancer Center
2010–2022
Pacific Ovarian Cancer Research Consortium
National Cancer Institute · P50
Contact PI · $7M · Fred Hutchinson Cancer Research Center
1999–2017

Clinical trials

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Site PI · Recruiting · Phase 3
SWOG Cancer Research Network
2026–2030
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
Site PI · Recruiting · Phase 3
SWOG Cancer Research Network
2025–2029
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027